论文部分内容阅读
近十年来,透皮控释系统(Transdermal Delivery System,简称TDS)的研究进展十分迅速,品种与数量与日俱增。目前,已研制成功或商品化的TDS至少有十种以上。其中包括东莨菪碱、硝酸甘油、可乐定、雌二醇等。 1986年8月在美国召开了第13届国际“生物活性材料控制释放”专题讨论会,在会议交流中,有关TDS的研究论文占有相当大的比例。TDS具有其它给药方式所没有的优点:1.可避免口服给药时药物受胃肠道生理因素的影响,吸收和代谢的个体差异较小。2.可持续给药,故对生物半衰期短的药物也适用。3.可避开肝脏与肠道“首过效应”的影响,生物利用度高。4.能提供一个治疗所需要的、接近零级的释药速率。5.使用方便,病人易于接受。6.可随时移去给药系统,终止给药。TDS是一种新颖、可行、有相当潜力
In recent ten years, the research of Transdermal Delivery System (TDS) has progressed rapidly and its varieties and numbers have been increasing day by day. At present, there are at least ten or more TDSs that have been successfully developed or commercialized. Including scopolamine, nitroglycerin, clonidine, estradiol and so on. In August 1986, the 13th International Symposium on “Controlled Release of Bioactive Materials” was held in the United States. During the conference exchange, the research papers on TDS accounted for a considerable proportion. TDS has the advantages of other modes of administration: 1 can be avoided when oral administration of drugs by gastrointestinal physiological factors, the individual differences in absorption and metabolism smaller. 2. Sustainable administration, it is also short for the biological half-life of the drug also applies. 3. Avoid the “first pass effect” of liver and intestine, high bioavailability. 4. Can provide a need for treatment, close to zero release rate. 5. Easy to use, the patient is easy to accept. 6. Can be removed at any time delivery system, termination of administration. TDS is a novel, feasible and has considerable potential